Virios Therapeutics Inc. (VIRI)
NASDAQ: VIRI
· Real-Time Price · USD
0.15
0.01 (8.77%)
At close: Oct 08, 2024, 8:00 PM
8.77% (1D)
| Bid | n/a |
| Market Cap | 206.5K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.68M |
| EPS (ttm) | -5.75 |
| PE Ratio (ttm) | -0.026956521739130435 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 42,356,733 |
| Avg. Volume (20D) | 87,787 |
| Open | 0.21 |
| Previous Close | 0.14 |
| Day's Range | 0.14 - 0.21 |
| 52-Week Range | 0.14 - 26.00 |
| Beta | 1.58 |
About VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, atten...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 17, 2020
Employees 4
Stock Exchange NASDAQ
Ticker Symbol VIRI
Website https://www.virios.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VIRI stock is "Hold." The 12-month stock price forecast is $15, which is an increase of 9577.42% from the latest price.
Stock Forecasts9 months ago
Virios Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
11 months ago
Virios Therapeutics shares are trading lower after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share.